» Articles » PMID: 36430306

Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism-In Vitro Study

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Nov 26
PMID 36430306
Authors
Affiliations
Soon will be listed here.
Abstract

This determination of the mitochondrial effect of pharmacologically different antidepressants (agomelatine, ketamine and vortioxetine) was evaluated and quantified in vitro in pig brain-isolated mitochondria. We measured the activity of mitochondrial complexes, citrate synthase, malate dehydrogenase and monoamine oxidase, and the mitochondrial respiratory rate. Total hydrogen peroxide production and ATP production were assayed. The most potent inhibitor of all mitochondrial complexes and complex I-linked respiration was vortioxetine. Agomelatine and ketamine inhibited only complex IV activity. None of the drugs affected complex II-linked respiration, citrate synthase or malate dehydrogenase activity. Hydrogen peroxide production was mildly increased by agomelatine, which might contribute to increased oxidative damage and adverse effects at high drug concentrations. Vortioxetine significantly reduced hydrogen peroxide concentrations, which might suggest antioxidant mechanism activation. All tested antidepressants were partial MAO-A inhibitors, which might contribute to their antidepressant effect. We observed vortioxetine-induced MAO-B inhibition, which might be linked to decreased hydrogen peroxide formation and contribute to its procognitive and neuroprotective effects. Mitochondrial dysfunction could be linked to the adverse effects of vortioxetine, as vortioxetine is the most potent inhibitor of mitochondrial complexes and complex I-linked respiration. Clarifying the molecular interaction between drugs and mitochondria is important to fully understand their mechanism of action and the connection between their mechanisms and their therapeutic and/or adverse effects.

Citing Articles

Linking Hypothermia and Altered Metabolism with TrkB Activation.

Alitalo O, Gonzalez-Hernandez G, Rosenholm M, Kohtala P, Matsui N, Muller H ACS Chem Neurosci. 2023; 14(17):3212-3225.

PMID: 37551888 PMC: 10485900. DOI: 10.1021/acschemneuro.3c00350.


Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity.

luptak M, Fisar Z, Hroudova J Antioxidants (Basel). 2023; 12(6).

PMID: 37371937 PMC: 10294837. DOI: 10.3390/antiox12061208.

References
1.
Holper L, Ben-Shachar D, Mann J . Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. Neuropsychopharmacology. 2018; 44(5):837-849. PMC: 6461987. DOI: 10.1038/s41386-018-0090-0. View

2.
Bansal Y, Kuhad A . Mitochondrial Dysfunction in Depression. Curr Neuropharmacol. 2016; 14(6):610-8. PMC: 4981740. DOI: 10.2174/1570159x14666160229114755. View

3.
Pei Q, Wang Y, Hu Z, Liu S, Tan H, Guo C . Evaluation of the highly variable agomelatine pharmacokinetics in Chinese healthy subjects to support bioequivalence study. PLoS One. 2014; 9(10):e109300. PMC: 4203722. DOI: 10.1371/journal.pone.0109300. View

4.
Millan M . Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol. 2022; 12:20451253221105128. PMC: 9251978. DOI: 10.1177/20451253221105128. View

5.
Emmerzaal T, Nijkamp G, Veldic M, Rahman S, Andreazza A, Morava E . Effect of neuropsychiatric medications on mitochondrial function: For better or for worse. Neurosci Biobehav Rev. 2021; 127:555-571. DOI: 10.1016/j.neubiorev.2021.05.001. View